Pulmonary sarcomatoid carcinoma (PSC) is a unique, highly invasive pulmonary
malignancy with a poor prognosis, representing 0.1–0.4% of all malignant lung tumors …

Background Pulmonary sarcomatoid carcinoma (PSC) is a unique subtype of non-small cell
lung cancer (NSCLC) with a high degree of malignancy and poor therapeutic effects. With …

Background Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive disease
without standardized treatment strategies. The efficacy of second-line or beyond immune …

Background Pulmonary sarcomatoid carcinoma (PSC) is a rare type of lung cancer. This
study aimed to explore the appropriate treatment for PSC. Methods Two cohorts were used …

Introduction Savolitinib has been found to have encouraging antitumor activity and a
favorable safety profile in Chinese patients with pulmonary sarcomatoid carcinoma and …

Simple Summary Pulmonary sarcomatoid carcinoma (PSC) is an aggressive subtype of non-
small-cell lung cancer (NSCLC). It does not respond favorably to standard chemotherapy …

Pulmonary sarcomatoid carcinomas belong to a group of neoplasms that remain
incompletely understood. They are rare tumors of the bronchopulmonary system that …

Objective This study aimed to investigate the incidence of the pulmonary sarcomatoid
carcinoma (PSC), to compare the clinical characteristics and overall survival (OS) of patients …

Pulmonary sarcomatoid carcinoma (PSC) is an unconventional non‐small‐cell lung cancer
(NSCLC) that is currently managed under guidelines used for conventional NSCLC and has …

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer,
which is resistant to the conventional chemotherapy and radiotherapy with a poor prognosis …